Medical Editor: John P. Cunha, DO, FACOEP
Vyzulta (latanoprostene bunod ophthalmic solution) 0.024%, for topical ophthalmic use is a prostaglandin analog indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Common side effects of Vyzulta include:
- eye redness and discharge,
- eye irritation,
- eye pain,
- eyelash changes,
- and pain on instilling the drops.
The dose of Vyzulta is one drop in the affected eye(s)once daily in the evening. If more than one topical ophthalmic drug is being used, the drugs should be administered with at least five (5) minutes between applications. Vyzulta may interact with other drugs. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Vyzulta; it is unknown how it would affect a fetus. It is unknown if Vyzulta passes into breast milk. Consult your doctor before breastfeeding.
Our Vyzulta (latanoprostene bunod ophthalmic solution) 0.024%, for Topical Ophthalmic Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
The following adverse reactions are described elsewhere in the labeling:
- Pigmentation [see WARNINGS AND PRECAUTIONS]
- Eyelash Changes [see WARNINGS AND PRECAUTIONS]
- Intraocular Inflammation [see WARNINGS AND PRECAUTIONS]
- Macular Edema [see WARNINGS AND PRECAUTIONS]
- Bacterial Keratitis [see WARNINGS AND PRECAUTIONS]
- Use with Contact Lens [see WARNINGS AND PRECAUTIONS]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
VYZULTA was evaluated in 811 patients in 2 controlled clinical trials of up to 12 months duration. The most common ocular adverse reactions observed in patients treated with latanoprostene bunod were: conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%). Approximately 0.6% of patients discontinued therapy due to ocular adverse reactions including ocular hyperemia, conjunctival irritation, eye irritation, eye pain, conjunctival edema, vision blurred, punctate keratitis and foreign body sensation.
Read the entire FDA prescribing information for Vyzulta (Latanoprostene Bunod Ophthalmic Solution)
© Vyzulta Patient Information is supplied by Cerner Multum, Inc. and Vyzulta Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.